

[Redacted]

Apologies for the delayed response.

We are in agreement with the CSAS report and have nothing to add at this stage. From current intelligence cancer drug commissioning will be going to the National Commissioning board and commissioners will want to be assured that this will be the case if NICE does not recommend this therapy.

Kind regards,

[Redacted signature]

**NHS Outer North East London - a partnership of local primary care trusts**

[Redacted contact information]

Delivered via MessageLabs

---